Michael Oscar Harhay

Michael Oscar Harhay

Auto-generated profile, based on publicly available information

Michael Oscar Harhay

University of Pennsylvania

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in JACC
Verified
Journal Article
Closed access
HBHiram Beltrán-Sánchez
Hiram Beltrán-Sánchez
MHMichael O. Harhay
Michael O. Harhay
MHMeera M. Harhay
Meera M. Harhay
SMSean McElligott
Sean McElligott

28 May 2015 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SHScott D. Halpern
Scott D. Halpern
BFBenjamin French
Benjamin French
DSDylan S. Small
Dylan S. Small
KSKathryn Saulsgiver
Kathryn Saulsgiver
MHMichael O. Harhay
Michael O. Harhay
KVKevin G. Volpp
Kevin G. Volpp
Financial incentives promote many health behaviors, but effective ways to deliver health incentives remain uncertain. We randomly assigned CVS Caremark employees and their relatives and friends to one of four incentive programs or to usual care for smoking cessation. Two of the incentive programs targeted individuals, and two targeted groups of six participants. One of the individual-oriented programs and one of the group-oriented programs entailed rewards of approximately $800 for smoking cessation; the others entailed refundable deposits of $150 plus $650 in reward payments for successful participants. Usual care included informational resources and free smoking-cessation aids. Overall, 2538 participants were enrolled. Of those assigned to reward-based programs, 90.0% accepted the assignment, as compared with 13.7% of those assigned to deposit-based programs (P<0.001). In intention-to-treat analyses, rates of sustained abstinence from smoking through 6 months were higher with each of the four incentive programs (range, 9.4 to 16.0%) than with usual care (6.0%) (P<0.05 for all comparisons); the superiority of reward-based programs was sustained through 12 months. Group-oriented and individual-oriented programs were associated with similar 6-month abstinence rates (13.7% and 12.1%, respectively; P=0.29). Reward-based programs were associated with higher abstinence rates than deposit-based programs (15.7% vs. 10.2%, P<0.001). However, in instrumental-variable analyses that accounted for differential acceptance, the rate of abstinence at 6 months was 13.2 percentage points (95% confidence interval, 3.1 to 22.8) higher in the deposit-based programs than in the reward-based programs among the estimated 13.7% of the participants who would accept participation in either type of program. Reward-based programs were much more commonly accepted than deposit-based programs, leading to higher rates of sustained abstinence from smoking. Group-oriented incentive programs were no more effective than individual-oriented programs. (Funded by the National Institutes of Health and CVS Caremark; ClinicalTrials.gov number, NCT01526265.)

1 October 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
NYNadir Yehya
Nadir Yehya
MHMichael O. Harhay
Michael O. Harhay
MCMartha A. Q. Curley
Martha A. Q. Curley
DSDavid A. Schoenfeld
David A. Schoenfeld
RRRon W. Reeder
Ron W. Reeder
Ventilator-free days (VFDs) are a commonly reported composite outcome measure in acute respiratory distress syndrome trials. VFDs combine survival and duration of ventilation in a manner that summarizes the “net effect” of an intervention on these two outcomes. However, this combining of outcome measures makes VFDs difficult to understand and analyze, which contributes to imprecise interpretations. We discuss the strengths and limitations of VFDs and other “failure-free day” composites, and we provide a framework for when and how to use these outcome measures. We also provide a comprehensive discussion of the different analytic methods for analyzing and interpreting VFDs, including Student’s t tests and rank-sum tests, as well as competing risk regressions treating extubation as the primary outcome and death as the competing risk. Using simulations, we illustrate how the statistical test with optimal power depends on the relative contributions of mortality and ventilator duration on the composite effect size. Finally, we recommend a simple analysis and reporting framework using the competing risk approach, which provides clear information on the effect size of an intervention, a statistical test and measure of confidence with the ability to adjust for baseline factors and allow interim monitoring for trials. We emphasize that any approach to analyzing a composite outcome, including other “failure-free day” constructs, should also be accompanied by an examination of the components.

15 October 2015 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
JBJustin C. Brown
Justin C. Brown
MHMichael O. Harhay
Michael O. Harhay
MHMeera N. Harhay
Meera N. Harhay
Background: Sarcopenia is a risk‐factor for all‐cause mortality among older adults, but it is unknown if sarcopenia predisposes older adults to specific causes of death. Further, it is unknown if the prognostic role of sarcopenia differs between males and females, and obese and non‐obese individuals.Methods: A population‐based cohort study among 4425 older adults from the Third National Health and Nutrition Survey (1988–1994). Muscle mass was quantified using bioimpedance analysis, and muscle function was quantified using gait speed. Multivariable‐adjusted Cox regression analysis examined the relationship between sarcopenia and mortality outcomes.Results: The mean age of study participants was 70.1 years. The prevalence of sarcopenia was 36.5%. Sarcopenia associated with an increased risk of all‐cause mortality [hazard ratio (HR): 1.29 (95% confidence interval (95% CI): 1.13–1.47); P < 0.001] among males and females. Sarcopenia associated with an increased risk of cardiovascular‐specific mortality among females [HR: 1.61 (95% CI: 1.22–2.12); P = 0.001], but not among males [HR: 1.07 (95% CI: 0.81–1.40; P = .643); Pinteraction = 0.079]. Sarcopenia was not associated with cancer‐specific mortality among males and females [HR: 1.07 (95% CI: 0.78–1.89); P = 0.672]. Sarcopenia associated with an increased risk of mortality from other causes (i.e. non‐cardiovascular and non‐cancer) among males and females [HR: 1.32 (95% CI: 1.07–1.62); P = 0.008]. Obesity, defined using body mass index (Pinteraction = 0.817) or waist circumference (Pinteraction = 0.219) did not modify the relationship between sarcopenia and all‐cause mortality.Conclusions: Sarcopenia is a prevalent syndrome that is associated with premature mortality among community‐dwelling older adults. The prognostic value of sarcopenia may vary by cause‐specific mortality and differ between males and females.

1 February 2010 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
MHMichael O Harhay
Michael O Harhay
JHJohn Horton
John Horton
POPiero Olliaro
Piero Olliaro
Parasites found in the human gastrointestinal tract can be largely categorized into two groups, protozoa and helminths. The soil-transmitted helminths (Ascaris lumbricoides, hookworm and Trichuris ...

1 September 2011 in Trends in Parasitology
Verified
Journal Article
Closed access
MHMichael O. Harhay
Michael O. Harhay
POPiero L. Olliaro
Piero L. Olliaro
DCDorcas Lamounier Costa
Dorcas Lamounier Costa
CCCarlos Henrique Nery Costa
Carlos Henrique Nery Costa